bgfoto/E+ via Getty Images Intra-Cellular's Caplyta Shows Promise in Major Depressive Disorder In a November article, I wrote about Intra-Cellular's (NASDAQ:ITCI) Caplyta (lumateperone), a drug approved to treat schizophrenia and bipolar depression. The article was particularly focused on the drug's potential for Major Depressive Disorder (MDD). I had high expectations for important Phase 3 readouts. (...) lumateperone’s innovative pharmacological profile, its potential to meet the unmet needs of MDD patien ...